Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Phone app retrains anxious minds of young cancer survivors

NCT ID NCT06682039

First seen Feb 01, 2026 · Last updated Jun 21, 2026 · Updated 21 times

Summary

This study tested a smartphone app designed to help teen and young adult cancer survivors manage anxiety. The app uses attention bias modification (ABM) to retrain the brain to focus away from threats and toward positive or neutral cues, plus gratitude exercises. Researchers enrolled 70 survivors aged 15–29 to see if the app was easy to use and acceptable, not yet whether it actually reduces anxiety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD MALIGNANT SOLID NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

    Seattle, Washington, 98109, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

smartphone-based attention bias modification (ABM) app with gratitude exercises

What this could lead to

If it works, this could offer a simple, self-guided way to ease anxiety in young cancer survivors without medication.

What could go wrong

This was a small, early feasibility study (70 people) focused on whether the app is usable and acceptable, not on proving it reduces anxiety. Results may not apply to all survivors.

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.